Protara Therapeutics Stock (NASDAQ: TARA)

Protara Therapeutics (NASDAQ:TARA) Stock, Quote.Headers.trade-ideas

Protara Therapeutics

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Stock_Whisper_Index_Logo_6-copy

Biotech

Health Care

Exclusives

Tech

Trading Ideas

$BTC

MARA

MSTR

ORCL

ROKU

SOUN

TARA

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

DocuSign.How-it-Works_2020_thumb_Update

News

Pre-Market Outlook

Movers

ASAN

CAMP

DOCU

FOXX

GXAI

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MTEM

ORIS

PGHL

PRFX

RBRK

SATL

SWBI

VRPX

ZBAO

ZSPC

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

oil-prices-5079975

Earnings

Equities

Eurozone

Commodities

Markets

RIME

RKDA

STEC

Crude Oil Edges Lower; US Initial Jobless Claims Increase

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

Press Releases

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Financing

Protara Announces Proposed Public Offering

Protara Announces Pricing of $100 Million Public Offering

Protara Announces Closing of $100 Million Public Offering

Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Protara Highlights Recent Updates and Anticipated 2025 Milestones

General

Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

C4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Editas Medicine

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Seres Therapeutics

Macrogenics

Nanobiotix

Nkarta

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Renovaro

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

2seventy bio

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

LifeSci Capital

HC Wainwright & Co.

Guggenheim

Oppenheimer

Comments

Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga